1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,027 | 0,067 | 12:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Moss Genomics Inc.: Moss Genomics Reports Bitcoin Cash (BCH) Mining Activity | 234 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") has announced it has mined a block on the Bitcoin... ► Artikel lesen | |
| 13.11.25 | Moss Genomics Inc: Moss Genomics closes $100,000 private placement | 3 | Stockwatch | ||
| 13.11.25 | Moss Genomics Inc.: Moss Genomics Announces Closing of Financing Round | 558 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") announces that, effective as of November 11, 2025... ► Artikel lesen | |
| 11.07.25 | Moss Genomics Inc.: Moss Genomics Advances Blockchain Integration Strategy | 2.039 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is providing an update on its Ethereum (ETH) Treasury... ► Artikel lesen | |
| 19.06.25 | Moss Genomics Inc.: Moss Genomics Announces Strategic Investment in Genomes.io | 477 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce that on June 18, 2025, it has... ► Artikel lesen | |
| 28.04.25 | Moss Genomics Inc.: Moss Genomics Launches "Perennial" Genomics Platform, Closes on 130 ETH | 635 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce the public launch of its genomics... ► Artikel lesen | |
| 11.04.25 | Moss Genomics Inc.: Moss Genomics Announces Listing on the OTC Markets | 487 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 11, 2025) - Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the "Company" or "Moss") is pleased to announce that its common shares are... ► Artikel lesen | |
| MOSS GENOMICS Aktie jetzt für 0€ handeln | |||||
| 26.02.25 | Moss Genomics Inc. Announces Leadership Changes | 269 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) ("Moss" or the "Company") is pleased to announce the appointment of Joseph De Pinto to... ► Artikel lesen | |
| 25.02.25 | Moss Genomics Inc.: Moss Genomics Announces Genomics Business Update, Integrating Blockchain for Genomic Security and Transparency | 287 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 25, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to provide an update on its business strategy... ► Artikel lesen | |
| 04.02.25 | Moss Genomics Inc.: Moss Genomics Announces Private Placement and Agreement to Acquire Ethereum | 644 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce a non-brokered private placement of up... ► Artikel lesen | |
| 01.02.25 | Moss Genomics Inc.: Moss Genomics Announces Closing of Private Placement, Acquisition of 160 Ethereum Cryptocurrency (ETH) and Welcomes Hunter Jordan to Its Board of Directors | 1.388 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to announce that is has closed its previously announced... ► Artikel lesen | |
| 24.01.25 | Moss Genomics Inc.: Moss Genomics Provides Corporate Update and Announces Shift in Business Strategy | 1.021 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 24, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss") is pleased to provide an update on the Company's operations and... ► Artikel lesen | |
| 14.01.25 | Moss Genomics Inc. Announces Successful German Listing on the Frankfurt Stock Exchange (FSE) | 379 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (the "Company" or "Moss Genomics") is pleased to announce that it has successfully listed... ► Artikel lesen | |
| 14.01.25 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA 14.01.2025 | 500 | Xetra Newsboard | The following instruments on XETRA do have their first trading 14.01.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.01.2025
Aktien
1 CA61965T1012 Moss Genomics Inc.
2... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,90 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | 0,00 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| ALUMIS | 17,920 | 0,00 % | Alumis prices $300M upsized public offering | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | 0,00 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates | ||
| TANGO THERAPEUTICS | 11,790 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| PRAXIS PRECISION MEDICINES | 292,53 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| ADMA BIOLOGICS | 18,820 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,680 | 0,00 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,390 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 52,88 | 0,00 % | Regencell Bioscience is the top performing pharma stock YTD |
Das Unternehmen MOSS GENOMICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,027 Euro und damit -19,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOSS GENOMICS INC finden Sie auf Wallstreet Online.